

Breakdown of all of the Philips Respironics CPAP/BiPAP sleep devices test results and conclusions from December 2021 through July 2023.

Philips Respironics has additional conclusions for the first-generation DreamStation, System One and DreamStation Go products. We are committed to your safety and want you to be confident in using your device, but understand that testing can be very technical and therefore challenging to understand. So, let's break down the findings from independent, certified testing laboratories and qualified third-party experts including toxicologists and medical experts. If you would like to read the full report and test methods, you can find them at:

www.philips.com/src-july-update.



For the past 24 months testing has taken place with:



Representative of

100,000 DreamStation units from an algorithm analysis for the US and Canada

- 2,011 of these devices had degraded foam
- Results showed that 17X more degradation was present if using ozone cleaning

152,000 DreamStation units from an algorithm analysis for the EU with 17 devices with degradation

241,000 DreamStation units from an algorithm analysis for Japan with 3 devices with degradation

Volatile Organic Compound (VOCs) 129 devices were tested

Testing suggests there was no measurable harm as the exposure to the VOCs is below the standard.

Particulate Matter (PM) 264 devices were tested

Visual inspection suggests that pieces of foam are likely to accumulate and may not be directly emitted by the device. This is also supported by the measurement of the PM being within standard limits.

In addition to the above, completed testing and analyses on System One and DreamStation Go sleep therapy devices that have been exposed to ozone cleaning show that exposure to VOC and PM emissions from the assessed devices treated with ozone cleaning is unlikely to result in measurable harm. **Please note that Ozone and UV light cleaning products are not currently approved cleaning methods for sleep apnoea devices or masks and should not be used.**



Cancer Risk

External scientific experts have performed an [independent literature review](#) to evaluate if CPAP/BiPAP devices for obstructive sleep apnoea (OSA) treatment are associated with a risk for cancer. No statistical increase in cancer risk due to use of PAP devices has been found including those that used Philips Respironics devices compared to other brands.